News Room
Technophage Reaches Last Patient First Visit in REVERSE 2 Trial for TP-102
We are thrilled to share a major milestone in Technophage’s TP-102 clinical trial – REVERSE 2 – with the Last Patient First Visit (LPFV) now...
Technophage Initiates Phase 1b/2a Clinical Trial of TZ-161 for Acute Spinal Cord Injury
Technophage S.A., a clinical-stage biopharmaceutical company focused on developing innovative therapies for areas of unmet medical need, today...
Technophage has been granted with the ‘COTEC Innovative Status 2025’
Technophage is proud to announce that it has recently been granted with the ‘COTEC Innovative Status 2025’. COTEC Portugal is the main Portuguese...
Pipeline
Invest in our products
GMP manufacturing
Learn more about GMP manufacturing
Technophage
Who we are, What we do
Therapeutic
areas
TechnoPhage is committed to the development of biological and chemical products for infection, neurosciences and ophthalmology